Cover Image
市場調查報告書

Genzyme Corporation:產品平台分析

Genzyme Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251669
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
Genzyme Corporation:產品平台分析 Genzyme Corporation - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 74 Pages
簡介

Genzyme Corporation 是以稀有特殊的醫療未滿足需求為對象開發生命科學領域的技術,進行應用的生物科技企業。特別致力於稀少遺傳性疾病和腎臟疾病,整形外科,器官移植,癌症,免疫疾病的治療。該公司也致力於循環系統疾病和神經退化性疾病等領域的產品開發。

本報告提供Genzyme Corporation 的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新新聞和發表。

Genzyme Corporation的基本資料

  • Genzyme Corporation的概要
  • 主要資訊
  • 企業資料

Genzyme Corporation :R&D概要

  • 主要的治療範圍

Genzyme Corporation :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Genzyme Corporation :開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Genzyme Corporation :藥物簡介

  • eliglustat tartrate
  • patisiran
  • revusiran
  • sargramostim
  • GZ-402666
  • fresolimumab
  • Genz-682452
  • GZ-402671
  • Olipodase
  • GZ-402663
  • GZ-402668
  • 1D-11
  • Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy
  • Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy
  • GENZ-644442
  • GENZ-668764
  • Small Molecules for Malaria
  • Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A

Genzyme Corporation :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Genzyme Corporation :最近的開發平台趨勢

Genzyme Corporation :暫停中的計劃

Genzyme Corporation :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • ataluren
    • Genz-644470
    • GZ-402674
    • GZ-404477
    • metelimumab
    • tasidotin hydrochloride
    • teriflunomide
    • tolevamer potassium sodium

Genzyme Corporation :總公司和子公司的所在地

Genzyme Corporation :主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07959CDB

Summary

Global Markets Direct's, 'Genzyme Corporation - Product Pipeline Review - 2016', provides an overview of the Genzyme Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genzyme Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Genzyme Corporation
  • The report provides overview of Genzyme Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Genzyme Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Genzyme Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Genzyme Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genzyme Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genzyme Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Genzyme Corporation Snapshot
    • Genzyme Corporation Overview
    • Key Information
    • Key Facts
  • Genzyme Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Genzyme Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Genzyme Corporation - Pipeline Products Glance
    • Genzyme Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Genzyme Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Genzyme Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Genzyme Corporation - Drug Profiles
    • patisiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sargramostim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vandetanib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GZ-402666
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • olipudase alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ibiglustat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GZ-402668
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VYAADC-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 1D-11
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GENZ-644442
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Malaria
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genzyme Corporation - Pipeline Analysis
    • Genzyme Corporation - Pipeline Products by Target
    • Genzyme Corporation - Pipeline Products by Route of Administration
    • Genzyme Corporation - Pipeline Products by Molecule Type
    • Genzyme Corporation - Pipeline Products by Mechanism of Action
  • Genzyme Corporation - Recent Pipeline Updates
  • Genzyme Corporation - Dormant Projects
  • Genzyme Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GZ-402674
      • GZ-404477
      • tasidotin hydrochloride
      • teriflunomide
      • tolevamer potassium sodium
      • vandetanib
  • Genzyme Corporation - Locations and Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Genzyme Corporation - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Genzyme Corporation, Key Information
  • Genzyme Corporation, Key Facts
  • Genzyme Corporation - Pipeline by Indication, 2016
  • Genzyme Corporation - Pipeline by Stage of Development, 2016
  • Genzyme Corporation - Monotherapy Products in Pipeline, 2016
  • Genzyme Corporation - Partnered Products in Pipeline, 2016
  • Genzyme Corporation - Partnered Products/ Combination Treatment Modalities, 2016
  • Genzyme Corporation - Phase III, 2016
  • Genzyme Corporation - Phase II, 2016
  • Genzyme Corporation - Phase I, 2016
  • Genzyme Corporation - Preclinical, 2016
  • Genzyme Corporation - Discovery, 2016
  • Genzyme Corporation - Pipeline by Target, 2016
  • Genzyme Corporation - Pipeline by Route of Administration, 2016
  • Genzyme Corporation - Pipeline by Molecule Type, 2016
  • Genzyme Corporation - Pipeline Products by Mechanism of Action, 2016
  • Genzyme Corporation - Recent Pipeline Updates, 2016
  • Genzyme Corporation - Dormant Developmental Projects,2016
  • Genzyme Corporation - Discontinued Pipeline Products, 2016
  • Genzyme Corporation, Other Locations
  • Genzyme Corporation, Subsidiaries
  • Genzyme Corporation, Key Manufacturing Facilities

List of Figures

  • Genzyme Corporation - Pipeline by Top 10 Indication, 2016
  • Genzyme Corporation - Pipeline by Stage of Development, 2016
  • Genzyme Corporation - Monotherapy Products in Pipeline, 2016
  • Genzyme Corporation - Partnered Products in Pipeline, 2016
  • Genzyme Corporation - Pipeline by Top 10 Target, 2016
  • Genzyme Corporation - Pipeline by Route of Administration, 2016
  • Genzyme Corporation - Pipeline by Molecule Type, 2016
  • Genzyme Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top